Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Something is happening behind the scene. The next communication we get from the company may be the terms of either a deal, partial buyout or buyout (Amgen being the buyer). Despite being poorly managed, the company has a lot going on: ongoing AXAL Phase III, Europe marketing application submitted, conditional vet approval, prostate combo trial with Merck and $500 million deal on NEO with Amgen, as well as HOT. If there's a buyout, I think it will be for at least $500 million/$10 a share. That's the value of the Amgen deal. If Amgen believes in the technology, it may want to buy the company now to prevent anyone else from licensing HOT and also to have rights on PD1 combo trials such as the Merck and Bristol collaborations. I think we will find out soon. Those five executives didn't just step down all on their own the same day, and if the company planned to remain independent it would need those employees and a permanent CEO. And the article by the CFO touting traits of good CFO stewardship was odd to comical since her actions and unrestrained spending at ADXS over the last five years and destruction of shareholder value are the exact opposite of what she wrote about. I bet she was given a bit more time to start looking for a job since she is young, was O'Connor's puppet and anyway you look at it from a financial perspective she's going to have a hard time getting another CFO job given she oversaw such poor stewardship of investors capital in her tenure.